COLL - Collegium Pharmaceutical - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

COLL is currently covered by 6 analysts with an average price target of $46.33. This is a potential upside of $6.81 (17.23%) from yesterday's end of day stock price of $39.52.

Collegium Pharmaceutical's activity chart (see below) currently has 86 price targets and 91 ratings on display. The stock rating distribution of COLL is 65.38% BUY and 34.62% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 65.69% with an average time for these price targets to be met of 888.89 days.

Highest price target for COLL is $50, Lowest price target is $37, average price target is $42.83.

Most recent stock forecast was given by BRANDON FOLKES from CANTOR FITZGERALD on 11-Aug-2025. First documented stock forecast 01-Jun-2015.

Currently out of the existing stock ratings of COLL, 17 are a BUY (65.38%), 9 are a HOLD (34.62%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$44

$6.26 (16.59%)

$40

10 days ago
(11-Aug-2025)

10/11 (90.91%)

$7.86 (21.75%)

1074

Hold

$37

$-0.74 (-1.96%)

$36

3 months 12 days ago
(09-May-2025)

17/18 (94.44%)

$8.11 (28.07%)

811

Buy

$46

$8.26 (21.89%)

$46

4 months 12 days ago
(09-Apr-2025)

23/25 (92%)

$19.63 (74.44%)

553

Buy

$50

$12.26 (32.49%)

$50

4 months 28 days ago
(24-Mar-2025)

5/9 (55.56%)

$19.44 (63.61%)

700

Buy

$40

$2.26 (5.99%)

$44

9 months 10 days ago
(11-Nov-2024)

1/3 (33.33%)

$7.82 (24.30%)

316

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is COLL (Collegium Pharmaceutical) average time for price targets to be met?

On average it took 888.89 days on average for the stock forecasts to be realized with a an average price target met ratio 65.69

Which analyst has the current highest performing score on COLL (Collegium Pharmaceutical) with a proven track record?

DAVID STEINBERG

Which analyst has the current lower performing score on COLL (Collegium Pharmaceutical) with a proven track record?

GLEN SANTANGELO

Which analyst has the most public recommendations on COLL (Collegium Pharmaceutical)?

David Steinberg has 2 price targets and 2 ratings on COLL

Which analyst is the currently most bullish on COLL (Collegium Pharmaceutical)?

Oren Livnat with highest potential upside - $12.26

Which analyst is the currently most reserved on COLL (Collegium Pharmaceutical)?

Tim Lugo with lowest potential downside - -$32.06

Collegium Pharmaceutical in the News

Collegium Pharmaceutical Inc (NASDAQ:COLL) Reports Record Q2 2025 Earnings and Raises Full-Year Guidance

COLLEGIUM PHARMACEUTICAL INC (NASDAQ:COLL [https://www.chartmill.com/stock/quote/COLL]) REPORTS STRONG Q2 2025 EARNINGS, BEATS ESTIMATES Collegium Pharmaceutical Inc delivered a solid performance in the second quarter of 2025, surpassing analyst expectations on both revenue and earnings per share (EPS). The company reported RECORD QUARTERLY NET REVENUE OF $188.0 MILLION, marking a 29% YEAR-OVER-YEAR INCREASE and exceeding the consensus...

Collegium Pharmaceutical Non-GAAP EPS of $1.68 misses by $0.17, revenue of $188M beats by $7.12M

* Collegium Pharmaceutical press release [https://seekingalpha.com/pr/20192911-collegium-reports-second-quarter-2025-financial-results-raises-2025-outlook] (NASDAQ:COLL [https://seekingalpha.com/symbol/COLL]): Q2 Non-GAAP EPS of $1.68 misses by $0.17. * Revenue of $188M (+29.4% Y/Y) beats by $7.12M. *   MORE ON COLLEGIUM PHARMACEUTICAL * Collegium Pharmaceutical: Stock Deserves A ‘Buy’ Call On Undervaluation Of ADHD Drug [https://seekingalpha.com/article/4798405-collegium-pharmaceutical-stock-deserves-buy-call-undervaluation-adhd-drug] * Collegium Pharmaceutical Q2 2025 Earnings Preview [https://seekingalpha.com/news/4480050-collegium-pharmaceutical-q2-2025-earnings-preview] * Collegium...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?